CD4 and COVID-19: Cross-reactive CD4+ T cells that can cross-recognize SARS-CoV-2 and endemic HCoVs have been demonstrated in COVID-19–unexposed donors, COVID-19–recovered individuals, and vaccine recipients (19–28).